These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38723624)

  • 21. Nomograms Combining Clinical and Imaging Parameters to Predict Recurrence and Disease-free Survival After Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer.
    Zhang Y; Liu L; Zhang K; Su R; Jia H; Qian L; Dong J
    Acad Radiol; 2023 Mar; 30(3):499-508. PubMed ID: 36050264
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between cancer immunity and treatment results in uterine cervical cancer patients treated with radiotherapy.
    Someya M; Tsuchiya T; Fukushima Y; Hasegawa T; Takada Y; Hori M; Miura K; Kitagawa M; Gocho T; Hirohashi Y; Torigoe T; Iwasaki M; Matsuura M; Saito T; Sakata KI
    Jpn J Clin Oncol; 2020 Oct; 50(11):1290-1297. PubMed ID: 33089868
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapy-free interval has prognostic value in patients with recurrent cervical cancer treated with chemotherapy following definitive concurrent chemoradiotherapy.
    Kozaki M; Sakuma S; Kudaka W; Kinjyo Y; Taira Y; Arakaki Y; Shimoji Y; Nakasone T; Nakamoto T; Wakayama A; Ooyama T; Aoki Y
    Arch Gynecol Obstet; 2017 Nov; 296(5):997-1003. PubMed ID: 28884382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical efficacy of nedaplatin-based concurrent chemoradiotherapy for uterine cervical cancer: a Tohoku Gynecologic Cancer Unit Study.
    Kagabu M; Shoji T; Murakami K; Omi H; Honda T; Miura F; Yokoyama Y; Tokunaga H; Takano T; Ohta T; Shimizu D; Sato N; Soeda S; Watanabe T; Yamada H; Mizunuma H; Yaegashi N; Nagase S; Tase T; Sugiyama T
    Int J Clin Oncol; 2016 Aug; 21(4):735-740. PubMed ID: 26782958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Completion hysterectomy after chemoradiotherapy for locally advanced adeno-type cervical carcinoma: updated survival outcomes and experience in post radiation surgery.
    Yang J; Yang J; Cao D; Shen K; Ma J; Zhang F
    J Gynecol Oncol; 2020 Mar; 31(2):e16. PubMed ID: 31912674
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlations between alterations of T-helper 17 cells and treatment efficacy after concurrent radiochemotherapy in locally advanced cervical cancer (stage IIB-IIIB): a 3-year prospective study.
    Liu Y; Guo QF; Chen JL; Li XR; Hou F; Liu XY; Zhang WJ; Zhang Y; Gao FF; Zhang YZ; Cui BX; Liu NF
    Chin Med J (Engl); 2021 Apr; 134(8):954-962. PubMed ID: 33840740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of treatment response from the microenvironment of tumor immunity in cervical cancer patients treated with chemoradiotherapy.
    Someya M; Tsuchiya T; Fukushima Y; Hasegawa T; Hori M; Kitagawa M; Gocho T; Mafune S; Ikeuchi Y; Hirohashi Y; Torigoe T; Iwasaki M; Matsuura M; Saito T; Matsumoto Y; Sakata KI
    Med Mol Morphol; 2021 Sep; 54(3):245-252. PubMed ID: 33963949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Value of Pretreatment Metabolic PET Parameters in Cervical Cancer Patients With Metabolic Complete Response After Concurrent Chemoradiotherapy.
    Son SH; Jeong SY; Chong GO; Lee YH; Park SH; Lee CH; Hong CM; Jeong JH; Lee SW; Ahn BC; Lee J
    Clin Nucl Med; 2018 Sep; 43(9):e296-e303. PubMed ID: 30036243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Total laparoscopic pelvic exenteration for a laterally recurrent cervical carcinoma with a vesicovaginal fistula that developed after concurrent chemoradiotherapy.
    Kanao H; Aoki Y; Hisa T; Takeshima N
    Gynecol Oncol; 2017 Aug; 146(2):438-439. PubMed ID: 28576262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma.
    Sheu BC; Chiou SH; Lin HH; Chow SN; Huang SC; Ho HN; Hsu SM
    Cancer Res; 2005 Apr; 65(7):2921-9. PubMed ID: 15805295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Multi-Institutional Retrospective Analysis of Oncologic Outcomes for Patients With Locally Advanced Cervical Cancer Undergoing Platinum-Based Adjuvant Chemotherapy After Concurrent Chemoradiotherapy.
    Wu N; Su X; Song H; Li Y; Gu F; Sun X; Li X; Cheng G
    Cancer Control; 2021; 28():1073274821989307. PubMed ID: 33593091
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mast Cell-Dependent CD8
    Bodduluri SR; Mathis S; Maturu P; Krishnan E; Satpathy SR; Chilton PM; Mitchell TC; Lira S; Locati M; Mantovani A; Jala VR; Haribabu B
    Cancer Immunol Res; 2018 Mar; 6(3):332-347. PubMed ID: 29382671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics, treatment patterns, and outcomes in patients with high-risk locally advanced cervical cancer.
    Coutinho F; Gokhale M; Doran C; Monberg M; Yamada K; Chen L
    Cancer Treat Res Commun; 2024; 39():100800. PubMed ID: 38430610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant chemotherapy versus concurrent chemoradiotherapy for high-risk cervical cancer after radical hysterectomy and systematic lymphadenectomy.
    Takekuma M; Kasamatsu Y; Kado N; Kuji S; Tanaka A; Takahashi N; Abe M; Hirashima Y
    Int J Clin Oncol; 2016 Aug; 21(4):741-747. PubMed ID: 26857458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneity of IFN-Mediated Responses and Tumor Immunogenicity in Patients with Cervical Cancer Receiving Concurrent Chemoradiotherapy.
    Chen J; Chen C; Zhan Y; Zhou L; Chen J; Cai Q; Wu Y; Sui Z; Zeng C; Wei X; Muschel R
    Clin Cancer Res; 2021 Jul; 27(14):3990-4002. PubMed ID: 33766815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete remission of advanced and recurrent cervical cancer with pembrolizumab treatment- 3 case reports.
    Tung HJ; Wang CC; Liu FY; Lai CH
    Taiwan J Obstet Gynecol; 2021 Sep; 60(5):938-941. PubMed ID: 34507680
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer.
    Oh D; Lee JE; Huh SJ; Park W; Nam H; Choi JY; Kim BT
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):549-54. PubMed ID: 24074928
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
    Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
    J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic value of ADC quantification for clinical outcome in uterine cervical cancer treated with concurrent chemoradiotherapy.
    Gu KW; Kim CK; Choi CH; Yoon YC; Park W
    Eur Radiol; 2019 Nov; 29(11):6236-6244. PubMed ID: 30980126
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas.
    Wang X; Wang T; Xu M; Xiao L; Luo Y; Huang W; Zhang Y; Geng W
    Hum Immunol; 2014 Dec; 75(12):1203-9. PubMed ID: 25446402
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.